Year-end Sale % OFF 
Abstract
Malaria remains a public health problem with still more than half a million deaths annually. Despite ongoing efforts of many countries, malaria elimination has been difficult due to emerging resistances against most traditional drugs, including artemisinin compounds - the most potent antimalarials currently available. Therefore, the discovery and development of new drugs with novel mechanisms of action to circumvent resistances is urgently needed. In this sense, one of the most promising areas is the exploration of transport proteins. Transporters mediate solute uptake for intracellular parasite proliferation and survival. Targeting transporters can exploit these processes to eliminate the parasite. Here, we focus on transporters of the Plasmodium falciparum-infected red blood cell studied as potential biological targets and discuss published drugs directed at them.
Highlights
Reviewed by: Marcos L Gazarini, Federal University of São Paulo, Brazil Roberto Rudge Moraes Barros, Federal University of São Paulo, Brazil
We focus on transporters of the Plasmodium falciparuminfected red blood cell studied as potential biological targets and discuss published drugs directed at them
This study focused on the physiology of the transporter and taken together with the high risk for toxicity of targeting a host cell transporter might explain why little follow-up studies against voltage dependent anion channel (VDAC) were conducted (Staines et al, 2010)
Summary
Reviewed by: Marcos L Gazarini, Federal University of São Paulo, Brazil Roberto Rudge Moraes Barros, Federal University of São Paulo, Brazil. We focus on transporters of the Plasmodium falciparuminfected red blood cell studied as potential biological targets and discuss published drugs directed at them. Plasmodial Transporters as Drug Targets with the advent of bioinformatics, the amount of identified transporters has expanded, encompassing more than 144 genes corresponding to 2.52% of the Plasmodium genome (Martin 2020).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
